drugmakers - International Biopharmaceutical Industry

news

FDA, as expected, rejects Lilly and Innovent immunotherapy in signal to drugmakers

Dive Brief: The Food and Drug Administration has rejected an experimental cancer immunotherapy Eli Lilly and partner Innovent Biologics have been developing for a ...

25 March 2022 news drugmakers | Eli Lilly

Continue Reading →

news

J&J to explore RNA reprogramming with Remix research deal

Dive Brief: Johnson & Johnson is partnering with Remix Therapeutics to develop drugs that are meant to reprogram how RNA is processed, becoming the latest big ...

18 February 2022 news drugmakers | J&J

Continue Reading →

news

After years of decline, drugmakers’ price hikes may have bottomed out

Double-digit list price increases for branded medicines in the middle of the last decade put drugmakers in political crosshairs. Under criticism and pressure, those b...

7 January 2022 news bottomed out | drug price

Continue Reading →

news

Latest Roche results show promise for new type of cancer immunotherapy

Though drugmakers have spent considerable resources trying to expand the reach of immunotherapy through new drug combinations, success has been hard to find. Multiple...

13 December 2021 news cancer immunotherapy | drugmakers

Continue Reading →

news

Blueprint, taking aim at larger drugmakers, becomes a biotech buyer

Lengo's drug targets a mutation in the gene that drives production of a protein called EGFR, which, in turn, can help spur tumor growth. The mutation, found in the ex...

3 December 2021 news Biotech | Blueprint

Continue Reading →

news

Vaccine makers move quickly to confront omicron threat

Several companies, including Pfizer and Moderna, are already at work adapting their coronavirus shots to the newly identified variant. Facing a coronavirus variant t...

3 December 2021 news coronavirus | drugmakers

Continue Reading →

news

Atea, Roche change plans for oral COVID-19 drug after trial setback

Atea's fast ascent last year was due to its plan to use a pill originally developed for hepatitis C infections as a treatment for COVID-19. The strategy resonated wit...

22 October 2021 news Atea | Biotech

Continue Reading →

news

Sanofi claims positive early data for mRNA COVID shot, but pivots to flu instead

When drugmakers geared up to respond to the pandemic, Sanofi and GSK, as two of the largest vaccine makers, were expected to make a major contribution. Protein-based ...

30 September 2021 news drugmakers | flu

Continue Reading →

news

Regeneron drug extends survival in lung cancer trial, lifting company’s hopes in field

Since its first approval in first-line lung cancer in 2016, Keytruda has proved a tough competitor for rival drugmakers to challenge with their own therapies. Bristol...

13 August 2021 news Bristol Myers Squibb | drugmakers

Continue Reading →

news

FDA rejects a biotech’s kidney drug, but some analysts still see a ‘sliver of hope’

The FDA's decision wasn't surprising to analysts, as "deficiencies" in an approval application have become somewhat of a prelude to rejection. This year alone saw two...

5 August 2021 news Acadia Pharmaceuticals | Ardelyx

Continue Reading →

Current Edition

Upcoming Events

Advertisement

FDA, as expected, rejects Lilly and Innovent immunotherapy in signal to drugmakers

J&J to explore RNA reprogramming with Remix research deal

After years of decline, drugmakers’ price hikes may have bottomed out

Latest Roche results show promise for new type of cancer immunotherapy

Blueprint, taking aim at larger drugmakers, becomes a biotech buyer

Vaccine makers move quickly to confront omicron threat

Atea, Roche change plans for oral COVID-19 drug after trial setback

Sanofi claims positive early data for mRNA COVID shot, but pivots to flu instead

Regeneron drug extends survival in lung cancer trial, lifting company’s hopes in field

FDA rejects a biotech’s kidney drug, but some analysts still see a ‘sliver of hope’

International Biopharmaceutical Industry